A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - Full Text View

Sponsor:	Diamyd Therapeutics AB
Information provided by (Responsible Party):	Diamyd Therapeutics AB
ClinicalTrials.gov Identifier:	NCT00751842

Purpose

The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.

Based on recent results from other clinical trials with the study drug it was unlikely this study would meet the intended primary or secondary efficacy endpoints. Therefore the primary focus in this study has changed to ensure that safety data is available for at least 6 months following the last dose of active study drug.

Condition	Intervention	Phase
Type 1 Diabetes Mellitus	Drug: rhGAD65 Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus (USA)

Resource links provided by NLM:

Genetics Home Reference related topics: 6q24-related transient neonatal diabetes mellitus

MedlinePlus related topics: Diabetes Medicines Diabetes Type 1

U.S. FDA Resources

Further study details as provided by Diamyd Therapeutics AB:

Primary Outcome Measures:

Meal Stimulated C-peptide (area under the curve) [ Time Frame: 15 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

HbA1c [ Time Frame: 15 months ] [ Designated as safety issue: No ]
Insulin Dose [ Time Frame: 15 months ] [ Designated as safety issue: No ]

Enrollment:	331
Study Start Date:	August 2008
Estimated Study Completion Date:	February 2012
Estimated Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: A This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.	Drug: rhGAD65 Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
Active Comparator: B This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.	Drug: rhGAD65 Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
Placebo Comparator: C This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.	Drug: Placebo Placebo injected subcutaneously at days 1, 30, 90 and 270.

Eligibility

Ages Eligible for Study:	10 Years to 20 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Main Inclusion Criteria:

Insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at time of screening
Fasting C-peptide level at time of screening above 0.1 nmol/L
Elevated GAD65 antibodies (GADA) at time of screening
Male and female patients between 10 and 20 years of age

Main Exclusion Criteria:

Treatment with immunosuppressants or any anti-diabetic medications other than insulin
A history of certain diseases or conditions (e.g. anemia, HIV, hepatitis, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)
Treatment with any vaccine within 1 month prior to planned first Diamyd dose or planned treatment with vaccine up to 2 months after the last injection with Diamyd, excluding the influenza vaccine
Participation in other clinical trials with a new chemical entity within the previous 3 months
Pregnancy or planned pregnancy within 1 year after the last Diamyd dose
Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00751842

Show 43 Study Locations

Sponsors and Collaborators

Diamyd Therapeutics AB

Investigators

Principal Investigator:

Jerry Palmer, Professor

University of Washington

More Information

Publications:

Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008 Oct 30;359(18):1909-20. Epub 2008 Oct 8.

Responsible Party:	Diamyd Therapeutics AB
ClinicalTrials.gov Identifier:	NCT00751842 History of Changes
Other Study ID Numbers:	D/P3/07/5
Study First Received:	September 11, 2008
Last Updated:	October 7, 2011
Health Authority:	United States: Food and Drug Administration

Keywords provided by Diamyd Therapeutics AB:

Diabetes
Juvenile Diabetes
Diabetes type 1
Autoimmune Diabetes
Insulin dependent Diabetes
Type 1 diabetes

Type 1 diabetes mellitus
Diamyd
rhGAD65
GAD
GAD-alum

Additional relevant MeSH terms:

Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases

Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on February 09, 2012